nach oben

World Journal of Urology

Erschienen in:

12.04.2017 | Original Article

Five-year outcomes of thulium vapoenucleation of the prostate for symptomatic benign prostatic obstruction

verfasst von: A. J. Gross, A. K. Orywal, B. Becker, C. Netsch

Erschienen in: World Journal of Urology | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Introduction and objectives

To assess the 5-year outcomes of thulium vapoenucleation of the prostate (ThuVEP) in patients with benign prostatic obstruction (BPO) retrospectively.

Methods

Five-hundred patients were treated with ThuVEP between January 2007 and January 2010 at our institution. Patients were reassessed 1 and 5-years after ThuVEP with International Prostate Symptom Score (IPSS), Quality of Life (QoL), urinary peak flow (Qmax), postvoid residual volume (PVR), PSA and prostate volume. Patient data were expressed as median (interquartile range).

Results

One-hundred and thirty-one patients completed the 5-year follow-up. According to preoperative prostate volume, patients were divided into two groups: group A (<60 ml, n = 80) and B (≥60 ml, n = 51). IPSS, QoL, Qmax, and PVR improved significantly at discharge and continued to do so during 5-year follow-up (p ≤ 0.001). At 1-year follow-up, prostate volume had decreased significantly (50 vs. 13 mL, p < 0.001) corresponding to a prostate volume reduction of 80.8%. PSA was significantly reduced at 5-year (0.72 µg/l) follow-up compared to preoperative PSA (3.39 µg/l, p ≤ 0.001). PSA-reduction (total 77.1%) at 5-year follow-up was significantly different between group A (70.2%) and B (83.5%) (p ≤ 0.006). IPSS was significantly lower in group B than in A (2.5 vs. 6, p < 0.001) at 5-year follow-up. Bladder neck contractures (n = 4) and urethral strictures (n = 4) occurred in 3.1% of the patients each. Three patients (2.3%) were re-treated for regrowth of prostatic tissue.

Conclusions

ThuVEP is a durable procedure with regard to micturition improvement and PSA-reduction. The reintervention rate after ThuVEP was low during long-term follow-up.

Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F, Speakman MJ, Stief CG (2010) Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol 58:384–397CrossRefPubMed

Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, McVary K, Novara G, Woo H, Madersbacher S (2015) A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol 67:1066–1096CrossRefPubMed

Gilling PJ, Wilson LC, King CJ, Westenberg AM, Frampton CM, Fraundorfer MR (2012) Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years. BJU Int. 109:408–411CrossRefPubMed

Gilling PJ (2013) Laser enucleation is increasingly becoming the standard of care for treatment of benign prostatic hyperplasia of all sizes. Eur Urol 63:868–869CrossRefPubMed

Lin Y, Wu X, Xu A, Ren R, Zhou X, Wen Y, Zou Y, Gong M, Liu C, Su Z, Herrmann TRW (2016) Transurethral enucleation of the prostate versus transvesical open prostatectomy for large benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials. World J Urol 34:1207–1219CrossRefPubMed

Bach T, Wendt-Nordahl G, Michel MS, Herrmann TRW, Gross AJ (2009) Feasibility and efficacy of Thulium:YAG laser enucleation (VapoEnucleation) of the prostate. World J Urol 27:541–545CrossRefPubMed

Netsch C, Engbert A, Bach T, Gross AJ (2014) Long-term outcome following Thulium VapoEnucleation of the prostate. World J Urol 32:1551–1558CrossRefPubMed

Bach T, Netsch C, Pohlmann L, Herrmann TR, Gross AJ (2011) Thulium:YAG vapoenucleation in large volume prostates. J Urol 186:2323–2327CrossRefPubMed

Gross AJ, Netsch C, Knipper S, Hölzel J, Bach T (2013) Complications and early postoperative outcome in 1080 patients after thulium vapoenucleation of the prostate: results at a single institution. Eur Urol 63:859–867CrossRefPubMed

10.

Tinmouth WW, Habib E, Kim SC, Kuo RL, Paterson RF, Terry CL, Elhilali M, Lingeman JE (2005) Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate: a marker for completeness of adenoma resection? J Endourol 19:550–554CrossRefPubMed

11.

Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213CrossRefPubMedPubMedCentral

12.

Mamoulakis C, Efthimiou I, Kazoulis S, Christoulakis I, Sofras F (2011) The modified Clavien classification system: a standardised platform for reporting complications in transurethral resection of the prostate. World J Urol 29:205–210CrossRefPubMed

13.

Gravas S, Bach T, Bachmann A, Drake M, Gacci M, Gratzke C, Madersbacher S, Mamoulakis S, Tikkinen KAO (2016). Guidelines on the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO) EAU. http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/

14.

Kuntz RM, Lehrich K, Ahyai SA (2008) Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year-follow-up results of a randomized clinical trial. Eur Urol 53:160–166CrossRefPubMed

15.

Gilling PJ, Aho TF, Frampton CM, King CJ, Fraunhofer MR (2008) Holmium enucleation of the prostate: results at 6 years. Eur Urol 53:744–749CrossRefPubMed

16.

Krambeck AE, Handa SE, Lingeman JE (2010) Experience with more than 1000 holmium laser prostate enucleations for benign prostatic hyperplasia. J Urol 2010(183):1105–1109CrossRef

17.

Elmansy HM, Kotb A, Elhilali MM (2011) Holmium laser enucleation of the prostate: long-term durability of clinical outcomes and complication rates during 10 years of follow-up. J Urol 186:1972–1976CrossRefPubMed

18.

Malek RS, Kuntzman RS, Barrett DM (2005) Photoselective potassiumtitanyl-phosphat laser vaporization of the benign obstructive prostate: observations on long-term outcomes. J Urol 174:1344–1348CrossRefPubMed

19.

Ruszat R, Seitz M, Wyler SF, Abe C, Rieken M, Reich O, Gasser TC, Bachmann A (2008) GreenLight laser vaporization of the prostate: single-center experience and long-term results after 500 procedures. Eur Urol 54:893–901CrossRefPubMed

20.

Hai M (2009) Photoselective vaporization of the prostate: five-year outcomes of entire clinic population. Urology. 73:807–810CrossRefPubMed

21.

Malde S, Rajagopalan A, Patel N, Simoes A, Choi W, Shrotri N (2012) Potassium-titanyl-phosphate laser photoselective vaporization for benign prostatic hyperplasia: 5-year follow-up from a district general hospital. J Endourol 26:878–883CrossRefPubMed

22.

Elshal AM, Elmansy HM, Elhilali MM (2012) Can we predict the outcome of 532 nm laser photoselective vaporization of the prostate? Time to event analysis. J Urol 188:1746–1753CrossRefPubMed

23.

Elshal AM, Elmansy HM, Elhilali MM (2013) Two laser ablation techniques for a prostate less than 60 mL: lessons learned 70 months after a randomized controlled trial. Urology 82:416–422CrossRefPubMed

24.

Elshal AM, Elkoushy MA, Elmansy HM, Sampalis J, Elhilali MM (2014) Holmium:YAG transurethral incision versus laser photoselective vaporization for benign prostatic hyperplasia in a small prostate. J Urol 191:148–154CrossRefPubMed

25.

Guo S, Müller G, Lehmann K, Talimi S, Bonkat G, Püschel H, Gasser T, Bachmann A, Rieken M (2015) The 80-W KTP GreenLight laser vaporization of the prostate versus transurethral resection of the prostate (TURP): adjusted analysis of 5-year results of a prospective non-randomized bi-center study. Lasers Med Sci 30:1147–1151CrossRefPubMed

26.

Otsuki H, Kuwahara Y, Kosaka T, Nakamura K, Tsukamoto T (2016) Sufficient volume ablation with photoselective vaporization of the prostate delivers 5-year durability and improves symptom relief for larger prostates. J Endourol 30:102–108CrossRefPubMed

27.

Liu C, Zheng S, Li H, Xu K (2010) Transurethral enucleation and resection of prostate in patients with benign prostatic hyperplasia by plasma kinetics. J Urol 184(6):2440–2445CrossRefPubMed

28.

Zhu L, Chen S, Yang S, Wu M, Ge R, Wu W, Liao L, Tan J (2013) Electrosurgical enucleation versus bipolar transurethral resection for prostates larger than 70 ml: a prospective, randomized trial with 5-year followup. J Urol 189:1427–1431CrossRefPubMed

29.

Chen S, Zhu L, Cai J, Zheng Z, Ge R, Wu M, Deng Z, Zhou H, Yang S, Wu W, Liao L, Tan J (2014) Plasmakinetic enucleation of the prostate compared with open prostatectomy for prostates larger than 100 grams: a randomized noninferiority controlled trial with long-term results at 6 years. Eur Urol 66:284–291CrossRefPubMed

30.

Madersbacher S, Lackner J, Brössner C, Röhlich M, Stancik I, Willinger M, Schatzl G (2005) Prostate Study Group of the Austrian Society of Urology. Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23,123 cases. Eur Urol 47:499–504CrossRefPubMed

Titel: Five-year outcomes of thulium vapoenucleation of the prostate for symptomatic benign prostatic obstruction
verfasst von: A. J. Gross
A. K. Orywal
B. Becker
C. Netsch
Publikationsdatum: 12.04.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 10/2017
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-017-2034-4

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction and objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2017

Cost-effective management of pelvic fracture urethral injuries

Characteristics and outcomes of ureteroscopic treatment in 2650 patients with impacted ureteral stones

Novel AR-V7 detection in whole blood samples in patients with prostate cancer: not as simple as it seems

Association of benign prostatic hyperplasia (BPH) volume and prostate cancer: consecutive data from an academic institution in respect to the current scientific view